Header Logo
Keywords
Last Name
Institution

Ryan Mark Zurakowski

TitleAssistant Professor
InstitutionUniversity of Delaware
DepartmentElectrical and Computer Engineering
Phone302-831-0331
vCardDownload vCard
    Other Positions
    TitleAssistant Professor
    InstitutionUniversity of Delaware
    DepartmentMathematical Sciences

    TitleAssistant Professor
    InstitutionUniversity of Delaware
    DepartmentCenter for Biomedical Engineering Research


    Collapse Research 
    Collapse research activities and funding
    R21AI078842     (ZURAKOWSKI, RYAN M)Jun 5, 2009 - May 31, 2012
    NIH/NIAID
    Analysis of Differential Resistance Emergence Risk for Differential Treatment App
    Role: Principal Investigator

    R21AI110288     (ZURAKOWSKI, RYAN M)Sep 1, 2014 - Aug 31, 2016
    NIH/NIAID
    HIV 2-LTR Dynamics and Cryptic Viremia
    Role: Principal Investigator

    R03AI136710     (ZURAKOWSKI, RYAN M)Mar 1, 2018 - Feb 29, 2020
    NIH/NIAID
    Evidence of cryptic replication in dolutegravir intensification data
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Venanzi Rullo E, Pinzone MR, Cannon L, Weissman S, Ceccarelli M, Zurakowski R, Nunnari G, O'Doherty U. Persistence of an intact HIV reservoir in phenotypically naive T cells. JCI Insight. 2020 Oct 15; 5(20). PMID: 33055422.
      View in: PubMed
    2. Shirazi J, Donzanti MJ, Nelson KM, Zurakowski R, Fromen CA, Gleghorn JP. Significant Unresolved Questions and Opportunities for Bioengineering in Understanding and Treating COVID-19 Disease Progression. Cell Mol Bioeng. 2020 Jul 27; 1-26. PMID: 32837585.
      View in: PubMed
    3. Jagarapu A, Piovoso MJ, Zurakowski R. An Integrated Spatial Dynamics-Pharmacokinetic Model Explaining Poor Penetration of Anti-retroviral Drugs in Lymph Nodes. Front Bioeng Biotechnol. 2020; 8:667. PMID: 32676500.
      View in: PubMed
    4. Jagarapu A, Piovoso MJ, Zurakowski R. Optimal control modulation of HIV reservoir formation rate by antigen infusion. Proc IEEE Conf Decis Control. 2019 Dec; 2019:5662-5667. PMID: 32874015.
      View in: PubMed
    5. Pinzone MR, Bertuccio MP, VanBelzen DJ, Zurakowski R, O'Doherty U. Next Generation Sequencing in a direct model of HIV infection reveals important parallels and differences to in vivo reservoir dynamics. J Virol. 2020 Feb 12. PMID: 32051279.
      View in: PubMed
    6. Jagarapu A, Mann R, Piovoso MJ, Zurakowski R. Positive feedback through inflammation creates bistable behavior in HIV tissue sanctuaries. Proc Am Control Conf. 2019 Jul; 2019:3456-3461. PMID: 32148339.
      View in: PubMed
    7. Cannon L, Vargas-Garcia CA, Jagarapu A, Piovoso MJ, Zurakowski R. HIV 2-LTR experiment design optimization. PLoS One. 2018; 13(11):e0206700. PMID: 30408070.
      View in: PubMed
    8. Vargas-Garcia C, Zurakowski R, Singh A. Synaptic transmission may provide an evolutionary benefit to HIV through modulation of latency. J Theor Biol. 2018 Oct 14; 455:261-268. PMID: 30048721.
      View in: PubMed
    9. Martinez-Picado J, Zurakowski R, Buzón MJ, Stevenson M. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. Retrovirology. 2018 Jan 30; 15(1):15. PMID: 29378611.
      View in: PubMed
    10. Cannon L, Jagarapu A, Vargas-Garcia CA, Piovoso MJ, Zurakowski R. Implications of Measurement Assay Type in Design of HIV Experiments. Proc IEEE Conf Decis Control. 2017 Dec; 2017:4106-4111. PMID: 29445252.
      View in: PubMed
    11. Jagarapu A, Cannon L, Zurakowski R. Experiment Design for Early Molecular Events in HIV Infection. Proc Am Control Conf. 2017 May; 2017:122-127. PMID: 29332992.
      View in: PubMed
    12. Abraham G, Jagarapu A, Cannon L, Zurakowski R. Order preservation of expected information content using Unscented Transform approximation of multivariate prior distributions in HIV 2-LTR experiment design. Proc IEEE Conf Decis Control. 2016 Dec; 2016:5597-5602. PMID: 29332990.
      View in: PubMed
    13. Cardozo EF, Piovoso MJ, Zurakowski R. Increased inflammation in sanctuary sites may explain viral blips in HIV infection. IET Syst Biol. 2016 Aug; 10(4):153-66. PMID: 27444025.
      View in: PubMed
    14. Cannon L, Garcia CAV, Piovoso MJ, Zurakowski R. Prospective HIV Clinical Trial Comparison by Expected Kullback-Leibler Divergence. Proc Am Control Conf. 2016 Jul; 2016:1295-1300. PMID: 29332991.
      View in: PubMed
    15. Zurakowski R. Using the Tools we Have: Low-efficacy Vaccines and HIV. EBioMedicine. 2015 Dec; 2(12):1867-8. PMID: 26844264.
      View in: PubMed
    16. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang Z, Sun H, Li JZ, Piovoso M, Shaw A, Dalmau J, Zangger N, Martinez-Picado J, Zurakowski R, Yu XG, Telenti A, Walker BD, Rosenberg ES, Lichterfeld M. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. J Virol. 2014 Sep 1; 88(17):10056-65. PMID: 24965451.
      View in: PubMed
    17. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J, Henrich TJ, Li JZ, Pereyra F, Zurakowski R, Walker BD, Rosenberg ES, Yu XG, Lichterfeld M. HIV-1 persistence in CD4(+) T cells with stem cell-like properties. Nat Med. 2014 Feb; 20(2):139-42. PMID: 24412925.
      View in: PubMed
    18. Cardozo EF, Luo R, Piovoso MJ, Zurakowski R. Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification. J Theor Biol. 2014 Mar 21; 345:61-9. PMID: 24378646.
      View in: PubMed
    19. Luo R, Cardozo EF, Piovoso MJ, Wu H, Buzon MJ, Martinez-Picado J, Zurakowski R. Modelling HIV-1 2-LTR dynamics following raltegravir intensification. J R Soc Interface. 2013; 10(84):20130186. PMID: 23658114.
      View in: PubMed
    20. Luo R, Piovoso MJ, Zurakowski R. Modeling uncertainty in single-copy assays for HIV. J Clin Microbiol. 2012 Oct; 50(10):3381-2. PMID: 22837324.
      View in: PubMed
    21. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R. HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics. PLoS One. 2012; 7(7):e40198. PMID: 22815727.
      View in: PubMed
    22. Cardozo EF, Zurakowski R. Robust closed-loop minimal sampling method for HIV therapy switching strategies. IEEE Trans Biomed Eng. 2012 Aug; 59(8):2227-34. PMID: 22652153.
      View in: PubMed
    23. Cortes LM, Zurakowski R. Resistance evolution in HIV - modeling when to intervene. Proc Am Control Conf. 2012; 2012:4053-4058. PMID: 25264400.
      View in: PubMed
    24. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R. Optimal antiviral switching to minimize resistance risk in HIV therapy. PLoS One. 2011; 6(11):e27047. PMID: 22073250.
      View in: PubMed
    25. Zurakowski R. Nonlinear observer output-feedback MPC treatment scheduling for HIV. Biomed Eng Online. 2011; 10:40. PMID: 21619634.
      View in: PubMed
    26. Luo R, Cannon L, Hernandez J, Piovoso MJ, Zurakowski R. Controlling the Evolution of Resistance. J Process Control. 2011 Mar 1; 21(3):367-378. PMID: 21516198.
      View in: PubMed
    27. Cardozo EF, Zurakowski R. Measurement error robustness of a closed-loop minimal sampling method for HIV therapy switching. Conf Proc IEEE Eng Med Biol Soc. 2011; 2011:116-9. PMID: 22254264.
      View in: PubMed
    28. Luo R, Piovoso MJ, Zurakowski R. Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data. Conf Proc IEEE Eng Med Biol Soc. 2011; 2011:3585-8. PMID: 22255114.
      View in: PubMed
    29. Zurakowski R, Churgin M, Perez C, Rodriguez M. Approximate-model closed-loop minimal sampling method for HIV viral-load minima detection. Proc Am Control Conf. 2011; 5418-5419. PMID: 23001383.
      View in: PubMed
    30. Rosero-Garcia EE, Zurakowski R. Closed-loop minimal sampling method for determining viral-load minima during switching. Proc Am Control Conf. 2010 Jul 29; 2010:460-461. PMID: 23087541.
      View in: PubMed
    31. Luo R, Piovoso MJ, Zurakowski R. Modeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching. Proc Am Control Conf. 2010; 2010:5155-5160. PMID: 24954972.
      View in: PubMed
    32. Zurakowski R, Wodarz D. Model-driven approaches for in vitro combination therapy using ONYX-015 replicating oncolytic adenovirus. J Theor Biol. 2007 Mar 7; 245(1):1-8. PMID: 17095020.
      View in: PubMed
    33. Zurakowski R, Teel AR. A model predictive control based scheduling method for HIV therapy. J Theor Biol. 2006 Jan 21; 238(2):368-82. PMID: 15993900.
      View in: PubMed
    Zurakowski's Networks
    Click the "See All" links for more information and interactive visualizations!
    Same Department Expand Description